Lu Lu, Qin Jiale, Chen Jiandong, Yu Na, Miyano Satoru, Deng Zhenzhong, Li Chen
Department of Human Genetics, Department of Ultrasound, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhejiang Provincial Key Laboratory of Genetic & Developmental Disorders, Zhejiang University School of Medicine, Hangzhou, China.
Comput Struct Biotechnol J. 2022;20:5713-5728. doi: 10.1016/j.csbj.2022.10.017. Epub 2022 Oct 17.
Since COVID-19 emerged in 2019, significant levels of suffering and disruption have been caused on a global scale. Although vaccines have become widely used, the virus has shown its potential for evading immunities or acquiring other novel characteristics. Whether current drug treatments are still effective for people infected with Omicron remains unclear. Due to the long development cycles and high expense requirements of de novo drug development, many researchers have turned to consider drug repositioning in the search to find effective treatments for COVID-19. Here, we review such drug repositioning and combination efforts towards providing better handling. For potential drugs under consideration, aspects of both structure and function require attention, with specific categories of sequence, expression, structure, and interaction, the key parameters for investigation. For different data types, we show the corresponding differing drug repositioning methods that have been exploited. As incorporating drug combinations can increase therapeutic efficacy and reduce toxicity, we also review computational strategies to reveal drug combination potential. Taken together, we found that graph theory and neural network were the most used strategy with high potential towards drug repositioning for COVID-19. Integrating different levels of data may further improve the success rate of drug repositioning.
自2019年新冠病毒出现以来,已在全球范围内造成了严重的痛苦和破坏。尽管疫苗已得到广泛使用,但该病毒已显示出其逃避免疫力或获得其他新特性的潜力。目前的药物治疗对感染奥密克戎的人是否仍然有效尚不清楚。由于从头研发药物的周期长且费用高,许多研究人员已转向考虑药物重新定位,以寻找治疗新冠病毒的有效方法。在此,我们回顾此类药物重新定位和联合用药的努力,以提供更好的应对措施。对于正在考虑的潜在药物,结构和功能方面都需要关注,特定类别的序列、表达、结构和相互作用是研究的关键参数。对于不同的数据类型,我们展示了已采用的相应不同的药物重新定位方法。由于联合用药可提高治疗效果并降低毒性,我们还回顾了揭示药物联合潜力的计算策略。综合来看,我们发现图论和神经网络是用于新冠病毒药物重新定位最常用且潜力巨大的策略。整合不同层面的数据可能会进一步提高药物重新定位的成功率。